Brief: Sorrento Therapeutics announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, an oral mpro inhibitor for Phase I trial in covid-19 patients
19/08/2022 14:01
Aug 19 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* SORRENTO THERAPEUTICS ANNOUNCES CHINA NATIONAL MEDICAL
PRODUCTS
ADMINISTRATION (NMPA) IND CLEARANCE OF STI-1558, AN ORAL MPRO
INHIBITOR FOR PHASE I TRIAL IN COVID-19 PATIENTS
Source text for Eikon: ID:nGNX2PCgfY
Further company coverage: SRNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20